Objective-Although there is clear evidence from randomised trials of the eVectiveness of mammographic screening in women over 50 in reducing mortality from breast cancer, the benefit of screening in younger women remains less certain. This paper describes a randomised controlled trial in progress to study the eVect on breast cancer mortality of annual mammographic screening of women starting at age 40-41.
Background
In 1987 the National Health Service Breast Screening Programme (NHSBSP) was introduced, with women aged 50-64 being invited for mammographic screening every three years, and women aged 65 and over being able to refer themselves for screening. 1 The decision to introduce screening was based mainly on evidence available at the time from two randomised trials: the Health Insurance Plan (HIP) study, carried out in New York in the 1960s, 2 and the Swedish Two Counties study conducted in the 1970s. 3 Both these studies showed reductions in breast cancer mortality in women invited for screening, but when analyses by age at entry were conducted the eVectiveness of screening seemed to be restricted to women aged 50 and over at entry to the studies.
However, determination of whether screening is beneficial in women below 50 was identified as a priority in the Forrest report, 1 and the "age" trial was designed as a result of this recommendation. Since then, a considerable amount of further information has emerged on the eVect of screening in younger women, but there is continuing debate on this issue. 4 5 Seven randomised trials have now been conducted of mammographic screening for breast cancer; but of these, only one, the Canadian NBSS, was designed specifically to look at the eVect of screening in women under 50. 6 Subgroup analyses of the other trials are possible but will be based on small numbers. However, in recent years a number of meta-analyses of these studies have been conducted, the results varying mainly according to the length of follow up of the diVerent studies included. The most recent such analysis showed an 18% reduction in mortality in women aged 40-49 at entry (risk ratio 0.82, 95% confidence interval 0.71 to 0.95), although some studies only included women from age 45. 7 An overview of the five Swedish studies showed a reduction in mortality of 23% in women under 50 at entry (RR 0.77, 95% CI 0.59 to 1.01). 8 Recent results from the Gothenburg trial showed a 45% reduction (RR 0.55, 95% CI 0.31 to 0.96) in the study group of women aged 39-49 9 oVered a mammographic screening every 18 months, relative to the control group.
However, doubts still remain about the length of time taken for a benefit to emerge, and the extent to which any such benefit is due to screening taking place after women reach age 50.
The Canadian NBSS included women aged 40-49 at entry, and at an average 8.5 years of follow up there was a non-significant excess of breast cancer mortality in women oVered screening, by mammography and clinical examination relative to a control group receiving a baseline clinical examination only (RR 1.36, 95% CI 0.84 to 2.21). 6 A provisional updated analysis at 10 years of follow up shows a relative risk of 1.10 (95% CI 0.78 to 1.54). 10 However, the use of a volunteer population, the possible eVect of the baseline examination in the control group, and doubts about the quality of mammography 11 have led to the general applicability of the results being questioned. 12
Design of the trial
The UKCCCR breast screening research subcommittee established a working group to draw up a protocol for a trial to study the effect of routine mammographic screening starting at age 40-41 on breast cancer mortality. This paper is the first publication of the trial design and methodology.
The trial was designed to study the eVect of invitation to mammographic screening starting at ages 40-41 compared with invitation at age 50, as in the current NHSBSP. The purpose of this design, as opposed to taking a cross section of women aged 40-49, was to avoid the problem of women reaching age 50 shortly after their entry to the trial and to ensure that the trial results would provide information relevant for deciding public health policy. The decision to use an annual screening interval was made to maximise the potential benefit; more frequent screening may be necessary in this age group because of both lower sensitivity of mammography, and due to faster tumour growth rates. 13 Women are randomised into two groups: a study group of 65 000 women who are invited for annual screening by mammography and a control group of 130 000 with no intervention. The study group will continue to be invited until women reach age 48. After age 50 both they and the control group will be invited to three-yearly screening in accordance with national policy. Two view mammography with a grid is used for the first screen, with single view thereafter unless otherwise indicated.
SAMPLE SIZE
The sample size of the trial was calculated to give an 80% probability of demonstrating as statistically significant, a 20% reduction in breast cancer mortality over a 10 year period at the 5% significant level using a one tailed test in the total study group compared with the control group. This could be achieved either with two equal groups of 85 000 subjects or with a control group of 130 000 and a study group of 65 000. The latter design, with fewer women in the study group, was chosen as being more cost eVective, as most of the trial costs are incurred by inviting and screening women in the study group. The sample size was based on an estimated breast cancer mortality of 3.3 per 1000 over 10 years in the control group among an initially disease free population, using the method described by Moss et al. 14 A one tailed test was considered justified because the aim of the trial was to establish the existence and size of any benefit, and there was no reason to consider a relative risk in the opposite direction as such a finding would not result in any change in policy in the UK.
Since the trial protocol was agreed, it has been suggested that a number of factors might combine to reduce the power of the study. One such factor is adjuvant treatment, which can have a significant eVect on survival in patients with early stage breast cancer. The use of such treatment is likely to increase, and a 10% reduction in the death of patients in 40% of cases over the 10 year trial follow up period would reduce the 10 year control group mortality by 4%-that is, from 3.3 per 1000 to 3.17 per 1000. This would reduce the power of the trial to 77%. However, another four years' follow up will be available before screening at age 50 is likely to aVect mortality in the control group and the power to detect a 20% reduction over 14 years is 90%.
Two other factors which might serve to reduce the power of the study are compliance (lower than the expected 70%) and unscheduled screening (either private or within the NHS) of the control group. Plans to assess these factors are included in the trial protocol.
No special arrangements are made within the trial for women with a family history of breast cancer. It is recognised that a number of such women, in both study and control groups, will be being screened through cancer genetic clinics.
POSSIBLE DISADVANTAGES OF SCREENING
One of the concerns raised about regular mammographic screening from age 40 is the possible harmful eVect of radiation in inducing additional breast cancers. Feig and Hendrick have recently estimated that annual mammography of 100 000 women for 10 consecutive years beginning at age 40 will result in at most eight breast cancer deaths during the lifetime of these women. 15 These estimates are based on annual two view mammography, and the estimates for the current trial will therefore be proportionately lower. Law has predicted that for women in the trial aged 40-44 the probability of cancer induction exceeds that of cancer detection for 4 in 10 000 women (at a dose of 2 mGy/film), falling to 1.2 in 10 000 women aged 45-49. 16 Guidelines have been produced for participating centres on the need to monitor the dose routinely, and to keep the dose as low as possible, particularly in those women with large breasts, who may be most at risk.
Another concern is the number of benign biopsies resulting from screening which would not otherwise have been carried out, together with the possibility of overdiagnosis of cancers which would not otherwise present clinically. The rate of benign biopsies resulting from screening is being monitored; however, the widespread adoption of techniques such as fine needle aspiration cytology and core biopsy, which avoid open surgical biopsy in nearly all benign cases, makes this a less important issue than previously. The invitation of all women for screening at age 50-52 in the national programme will enable the extent of any overdiagnosis to be estimated by comparison of the cumulative breast cancer incidence rates in the study and control group after the whole control group has been invited for screening.
Trial organisation
RECRUITMENT OF TRIAL CENTRES All centres participating in the trial are established NHSBSP centres performing routine screening in women aged 50 and over. Entry of centres to the study has been phased, with two centres entering in the first year (1991), a further seven in year two, and 14 additional centres entering between 1993 and 1996.
Most trial centres contribute about 2000 women to the study and 4000 to the control group, though some centres with large catchment areas are contributing larger numbers. Most centres randomise and invite women for screening over a 12 month period, though some of the initial centres had a longer intake period, and some carry out all invitations for the trial in a shorter time period each year.
ETHICAL COMMITTEE APPROVAL
All centres entering the trial obtain the approval of their local ethical committee. In March 1998 approval was obtained from the North Thames multicentre research ethics committee.
IDENTIFICATION OF WOMEN AND RANDOMISATION
Trial women in the relevant age range are identified from the patient lists of general practitioners, which are held on health authority databases. The health authority also produces for each GP in the practice, a list known as a Prior Notification List containing registration details of their patients in the screening batch. Amendments, such as change of address, eligibility to be screened, etc, are made by the GPs and the list is returned to the health authority for the randomisation process to be carried out. Randomisation software was provided by the FHS computer unit, and installed at each participating health authority.
Individual randomisation is carried out, stratified by GP practice, so that one third of the patients of any practice are allocated to the study group and the remainder to the control group. At the randomisation stage each woman's record is flagged with a unique three character trial code, indicating the trial, arm (that is, control or study), and current participating status. Each woman is also allocated a date of entry. Registration details of all women are transferred electronically from the health authority to the relevant screening centre, where screening appointments are made for those women allocated to the study group.
SCREENING INVITATION
Women in the study group are sent a letter of invitation and an information leaflet from the relevant trial centre, both in a standard form for the trial, though with some local variation. The letter of invitation states clearly that the woman is being asked to participate in a research trial. Acceptance of the invitation is taken to be informed consent to participate, though in some centres, local ethics committees have also requested completion of written consent forms. In general, only one screening invitation is sent, though a few trial centres send reminders in keeping with local policy. RESCREENING All eligible women (including previous nonattenders) are reinvited each year, with the exception of those women who have specifically stated that they do not wish to participate. The trial status code is amended so that no further invitations are sent, though such women remain in the study group. Prior Notification Lists are sent to GPs as before, and a specific information leaflet is included with a repeat invitation.
Women in whom breast cancer has been diagnosed are followed up according to the existing protocol in each screening centre.
The aim is to rescreen women at a 12 month interval. No woman should be rescreened less than 10 months after her previous screen; if a woman defers by more than two months she will not be rescreened until her next annual screen is due, in order to keep appointments in phase as far as possible.
MONITORING WOMEN WHO MOVE
Around 18% of women are expected to move during the 10 year course of the trial. The coordinating centre keeps track of such women, mainly using information supplied by the health authority. Trial code information is included with records transferred to her new health authority when a woman moves, and if she is in the study group she should get recalled for screening if her new health authority is part of the trial and she is at a participating GP practice. All study group women are also encouraged to contact their nearest participating trial centre when they move, if they do not receive an invitation to be rescreened 13 months after their last appointment.
DATA COLLECTED FROM CENTRES
The trial is coordinated from the Cancer Screening Evaluation Unit (CSEU), at the Institute of Cancer Research. The coordinating centre maintains a complete file of the basic identification details of the trial population. It organises the entry of units to the trial, collates summary statistics from participating centres, and monitors compliance, referral, and detection rates.
The fact that breast screening centres in the UK use a variety of computer systems has necessitated the writing of supplementary software by five diVerent software firms, in order to hold additional data for the trial (in particular, a trial code which flags all participating women) and to enable the download of information.
The data recorded on trial women on the screening centre's computing system are identical to those collected for women in the NHS Breast Screening Programme. At regular intervals, selected data are downloaded from each trial centre to the coordinating centre, where a complete database of trial women is held. These include the women's identification details (including NHS number), trial code, dates of invitation and screening where relevant, and outcome of screening. Data on breast cancer diagnosis and deaths are obtained from screening centres where known, but more complete data are obtained from other sources, as described below.
MONITORING CANCER INCIDENCE
Information on screen detected cancers is included in the data downloaded from trial centres. Where interval cancers after a negative screen, or cancers in the non-attenders or control group become known to a trial centre, these are also notified to the coordinating centre. It is acknowledged that there is a time lag in obtaining complete cancer registration data, and that the reporting of non-screen detected cases by individual screening centres will vary. To ensure more complete ascertainment, breast cancer cases in the appropriate age range are identified from pathology laboratories, cancer registries, and quality assurance centres, by researchers, and are cross matched with the trial population database.
PATHOLOGY REVIEW
A pathology review is being undertaken of all breast cancers identified in the trial in order to agree a consensus diagnosis on each case, in particular, tumour size, histological grade, and nodal status. Histopathology slides and forms are requested from the relevant pathology laboratories for all cases of breast cancer identified in the trial, in order that they can be independently reported on by a panel of three pathologists with considerable expertise in the breast screening field. Discussion at regular meetings of the panel enables a consensus to be reached for each case. This pathology review will form the basis of an interim analysis.
MONITORING BREAST CANCER MORTALITY
The entire trial population will be flagged at the NHS central register, and information on all deaths (including date and cause of death) will be notified to the coordinating centre. Information on cancer registrations will also be notified, ensuring that information on breast cancers in women moving out of trial districts should eventually be received.
Analysis

MORTALITY ANALYSIS
For each breast cancer death in which breast cancer is certified as the underlying cause, the date of diagnosis will be determined, with this information being obtained from cancer registries where it is not already known from existing data collection. Those deaths in patients diagnosed before the woman's date of entry to the trial will be excluded as screening cannot be of benefit. The mortality analysis will refer to a cohort of women in whom breast cancer had not been diagnosed at the start of the trial. It is proposed to carry out the first mortality analysis after an average of seven years' follow up. This is likely to be reached at the end of 2001, meaning that the analysis could be carried out in the second half of 2002, allowing six months for data collection and validation.
Analysis of the time since trial entry of any mortality eVect will provide information on the possible benefit of starting screening at diVerent ages.
ESTIMATING CONTROL GROUP CONTAMINATION
In each of three trial centres postal questionnaires were sent to 200 women aged 41 before the centre started screening, thus targetting women who would not be randomised. The results showed that fewer than 6% of responders reported ever having had a routine mammogram, with only 2% having had one in the previous year. Similar surveys are being conducted in the control population during the course of the trial.
ECONOMIC ANALYSIS
The economic evaluation for the trial is being carried out by a team of researchers based at Brunel and Newcastle Universities. The project began in December 1993 and was funded by the Medical Research Council until May 1996. Estimates are being made of the change in health service and women's resource use, and the costs associated with starting screening at age 40. These costs will be combined with trial data to give an average incremental cost for each additional cancer detected and each woman screened. Additionally, the project is investigating whether evaluations of health outcomes associated with breast cancer treatment, screening attendance and assessment, and the diagnostic phase diVer for women in their early 40s compared with women aged 50-64. When mortality estimates become available these data can be combined with the expected life years gained to give the average incremental cost per life year and quality adjusted life years gained.
INTERMEDIATE END POINTS
After a review of the trial instigated by the funding bodies in 1993 it was recommended that an interim analysis of sensitivity, prevalence to incidence ratio, and prognostic factors should be conducted, and the collection of detailed pathology data has been carried out to achieve this. It will be possible to carry out further such analyses at various times. Nevertheless, given that less is known about the natural history of breast cancer in this age group, breast cancer mortality in the two groups will remain the major outcome measure.
